Search for: "Alnylam Pharmaceuticals, Inc."
Results 1 - 11 of 11
Sorted by Relevance | Sort by Date
9 Jul, 2007 8:16 pm
By Christopher P. Singer -- Alnylam Pharmaceuticals, Inc. and Roche announced on July 9, 2007 that they have entered into a
non-exclusive license agreement in the area of RNA interference (RNAi) therapeutics. The agreement includes an upfront payment of $331 million from Roche to Alnylam, which includes cash payments, purchase...
1 Aug, 2007 7:07 pm
By Christopher P. Singer -- In an August 1, 2007 press release, Alnylam Pharmaceuticals, Inc. announced that the European Patent
Office has issued a Rule 51(4) notification for European Patent 1 407 044 (Tuschl II) which relates to RNA interference (RNAi) technology. In the same release, Alnylam also stated that...
26 Nov, 2007 9:49 pm
By Donald Zuhn -- Alnylam Pharmaceuticals, Inc. announced today that it has received a German patent (DE 10080167) in the
"Kreutzer-Limmer I" patent series. According to the Cambridge, Massachusetts-based RNA interference (RNAi) therapeutics company, the Kreutzer-Limmer I patent series is one of three
"fundamental patent" families that Alnylam has exclusively...
7 Mar, 2007 9:44 pm
By Donald Zuhn On March 7, 2007, INEX Pharmaceuticals Corp. and Alnylam Pharmaceuticals, Inc. announced that the United
States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 09/431,594, which covers nucleic acid-lipid compositions. According to the statement
released by INEX, the allowed claims cover[]...
25 Mar, 2008 9:56 pm
By Donald Zuhn -- In an Op-Ed piece appearing in last Saturday's edition of The Boston Globe, Alnylam Pharmaceuticals Inc. Chief
Executive Officer Dr. John Maraganore (at right) wrote about a "perfect storm" that is building against biomedical patent protection. In an article entitled, "Good for iPods, but bad
for...
5 Jul 3:13 am
... Globe writes on a patent rights/patent prosecution dispute among Max Planck GmbH and Alnylam Pharmaceuticals Inc. on one side
and MIT, the Whitehead Institute for Biomedical Research in Cambridge, and the University of ... , the suit claims. UMass opted to license its ownership in the Tuschl I inventions for
therapeutic purposes to companies other than Alnylam, according to the complaint. IPBiz notes that a rather secondary player to the invention,
UMass, is creating the problem on licensing. There ...
8 Mar, 2007 8:18 am
... a banner year. Two of its prime discoverers won the 2006 Nobel Prize in Medicine and Physiology. Sirna Therapeutics, Inc., which, along with Alnylam Pharmaceuticals, Inc., bestride the RNAi patent estate, was swallowed up by pharmaceutical giant, Merck & Company,
Inc.. And, both research and investment interest in RNAi have soared. In its March issue, Nature Biotechnology provides a snapshot of where the second generation of RNAi research
is heading by ...
15 Jul, 2008 4:57 am
... No. EP 1 230 375, owned by Cancer Research Therapeutics Ltd. of Cambridge, UK and exclusively licensed to Alnylam Pharmaceuticals,
Inc. The patent was opposed by several companies involved in commercializing RNA interference (RNAi), including Sanofi-Aventis Deutschland GmbH, Sirna Therapeutics, Nucleonics,
Inc., Quark Biotech, and Silence Therapeutics AG. The patent, commonly referred to as the "Glover patent" based on the name of the ...
5 Aug 5:35 am
... of the Atlantic (GenericsWeb) Biotechnology companies at forefront of global health innovation - post 1: GlaxoSmithKline & Alnylam
Pharmaceuticals (PatentlyBIOtech) Australia: Parliamentary inquiry into gene patenting (The IP Factor) Canada: In an economic ... s appeal dismissed, with no reference to ECJ in
case concerning SPC applications for combination products: Astellas Pharma Inc v Comptroller-General of Patents (PatLit) Provigil (Modafinil) - US: Judge restarts litigation over
Cephalon's ...
1 Feb, 2008 12:00 am
... Jan 2008: statement regarding patenting human life: (IPBiz), (Patently-O), Alnylam Pharmaceuticals secures UK patent covering
molecules that affect RNA interference: (SmartBrief), ... serves and finds specimen of use acceptable: In re ICE Futures US, Inc: (TTABlog), (IP Updates), Mesmerized by fame of
"VANITY FAIR" mark, TTAB sustains ... Chicago IP Litigation Blog), Fisher-Price - Icon Health & Fitness Inc. has sued Fisher-Price for patent infringement over technology
that electronically simulates ...
28 Mar, 2008 6:00 am
... compulsory licenses: (Generic Pharmaceuticals & IP), US: Follow-on biologic drugs and patent law: A potential disconnect?: (Patent Docs), US: Alnylam CEO forecasts ... Federal Court considers the meaning of 'relevant to work in the relevant art': Ajinomoto Co Inc v Nutrasweet Australia Pty
Ltd: (Mallesons Stephen Jaques), Society of Authors' ... if the plaintiff's unsuccessful claims were objectively reasonable: Bridgeport Music, Inc v WB Music Corp: (Patry
Copyright Blog), CardioNet - Trade Secret ...
Search on: Blawgs.FM | BlawgSearch Google Co-op |
Blawg.com | Bloglines | Feedster | Google Blog
Search | Technorati | Google | MSN | Yahoo!